**Description**

**A COMPOSITION FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME**

**Technical Field**

The invention relates to a composition formed for the treatment of chronic fatigue syndrome.

**State of the Art**

Today, the chronic fatigue syndrome is the feeling of fatigue that is persistent for at least 6 months and that is not easily improved by rest. The symptoms of the chronic fatigue syndrome are sore throat, sensitivity in the neck and axillary lymph nodes, muscle pain, causeless pain in the joints, headaches, non-restful sleep and post-exercise weakness for a period longer than 24 hours.

Also today, there is not present a well accepted medicament for the treatment of the chronic fatigue syndrome. The cortisone at low doses may be resorted to, but it must be used under the supervision of a specialist physician. The best method for relaxation is to do physical exercise.

The invention no. WO 1999/053921 entitled "Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH" discloses a composition comprising L-carnitine or an alkanoyl L-carnitine or a pharmaceutically acceptable salt thereof and NADH and/or NADPH, said composition being useful as a medicament for the treatment of chronic fatigue syndrome or Parkinson’s disease and as a dietary supplement for the persons performing tiresome physical exercise or for weak subjects.

The invention no. EP1274430B1 entitled "Use of cabergoline for the treatment of fibromyalgia and chronic fatigue syndrome" provides for the use of a heterocyclic amine-type compound, a substituted phenylazacycloalkane-type compound or a cabergoline-type compound in the preparation of a medicament for the treatment of the symptoms of the fibromyalgia syndrome or chronic fatigue syndrome.

The invention no. EP2289540B1 entitled "Alpha-1-antitrypsin for use in the treatment of chronic fatigue syndrome" relates to the use of alpha-1-antitrypsin for the preparation of the effective medicaments aimed at the treatment of the chronic fatigue syndrome. In addition, the present invention relates to the use of the plasma or other therapeutic forms having sufficient alpha-1-antitrypsin content for obtaining an alpha-1-antitrypsin dose of 6 mg or more per kg of body weight at a frequency of 1 to 31 days.

As a result, the presence of the need for a composition for the treatment of the chronic fatigue syndrome and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to provide for a treatment for the chronic fatigue syndrome.

Another object of the invention is to provide energy increase with an increase provided in the level of cAMP and cGMP owing to the PDE4 and PDE5 suppressing ability.

Another object of the invention is to provide energy support via AMPK activation.

Another object of the invention is to provide energy support by way of suppression of the lactic acid formation and the support of the TCA cycle.

Another object of the invention is to provide improvement in the chronic fatigue syndromes of the viral origin.

In order to achieve the aforesaid advantages, the invention is a composition for the treatment of the chronic fatigue syndrome, said composition being obtained by the components selected from the group comprising 3,7-bis(2-hydroxyethyl)icaritin and ginsenoside RE that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a composition for the treatment of chronic fatigue syndrome. The composition according to the invention contains 3,7-bis(2-hydroxyethyl)icaritin and ginsenoside RE.

3,7-bis(2-hydroxyethyl)icaritin, the ingredient of said composition, provides energy increase with an increase provided in the level of cAMP and cGMP owing to its PDE4 and PDE5 suppressing ability. 3,7-bis(2-hydroxyethyl)icaritin also provides energy support via AMPK activation. 3,7-bis(2-hydroxyethyl)icaritin also provides energy support by way of suppression of the lactic acid formation and the support of the TCA cycle. 3,7-bis(2-hydroxyethyl)icaritin also provides improvement in the chronic fatigue syndromes of the viral origin, owing to its antiviral activity.

Ginsenoside RE, another ingredient of the invention, provides energy support by reducing the lactic acid release and supporting the sugar uptake by the muscles. Ginsenoside RE also reduces the metabolic burden of the body by suppressing the transcetolase enzyme.

Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:

10-90% 3,7-bis(2-hydroxyethyl)icaritin,

90-10% ginsenoside RE.

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for the treatment of the chronic fatigue syndrome and the manufacture thereof for this purpose.

**CLAIMS**

1. A composition for the treatment of the chronic fatigue syndrome, said composition being obtained by the components selected from the group comprising 3,7-bis(2-hydroxyethyl)icaritin and ginsenoside RE that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 10-90% by weight 3,7-bis(2-hydroxyethyl)icaritin.
3. A composition according to Claim 1 characterized in that it comprises 90-10% by weight ginsenoside RE.
4. Use of the components according to Claims 1 to 4 obtained individually or in combinations from the group consisting of 3,7-bis(2-hydroxyethyl)icaritin and ginsenoside RE for the manufacture of a composition for the treatment of the chronic fatigue syndrome.

**ABSTRACT**

**A COMPOSITION FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME**

The invention relates to a composition formed for the treatment of chronic fatigue syndrome.

No figure.